Carl Erik Nord, Ann Lidbeck, Kerstin Orrhage, Svante Sjöstedt

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Rapid and sensitive diagnosis of Toxoplasma gondii infections by PCR

Gut bacterial microbiota and obesity

I.J. Schalk Clinical Microbiology and Infection

Approach to diagnosis of infective endocarditis

Anna Tinnert, Annika Hamlet, Ann-Mari Svennerholm

D. Khalil, M. Hultin, M.U. Rashid, B. Lund

Changes in the intestinal microbiota from adulthood through to old age

Time-trends for Gram-negative and multidrug-resistant Gram-positive bacteria associated with nosocomial infections in German intensive care units between.

Control of multidrug-resistant Gram-negative bacteria in low- and middle-income countries—high impact interventions without much resources N. Singh,

Herpes zoster in non-hospitalized children

Migrant health—a cause for concern?

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

Virological tools to diagnose and monitor hepatitis C virus infection

R. Cantón Clinical Microbiology and Infection

Hydatid disease Clinical Microbiology and Infection

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

E. Braun, K. Hussein, Y. Geffen, G. Rabino, Y. Bar-Lavie, M. Paul

Surveillance of Legionnaires’ disease in Austria

In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species Jacques Dubois, Claude St-Pierre Clinical.

Structure of grepafloxacin relative to activity and safety profile

Vector control: a cornerstone in the malaria elimination campaign

The normal gastric microflora and Helicobacter pylori; before, during and after treatment with omeprazole and amoxycillin Inger Adamsson, Charlotta Edlund,

Changes in fecal flora and comparative multiple-dose pharmacokinetics of ceftibuten, cefpodoxime proxetil and amoxycillin/clavulanate Jörg Hamacher,

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Sofie Arens, Jan Verhaegen, Ludo Verbist

Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.

Training for the infectious diseases speciality in Norway

Epidemiology of opportunistic infections in AIDS patients

Laboratory diagnosis and biosafety issues of biological warfare agents

Anna Tinnert, Annika Hamlet, Ann-Mari Svennerholm

Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteria Inga Odenholt, Elisabeth Löwdin,

Sepsis and neutropenia induced by clozapine

Levofloxacin in the treatment of ventilator-associated pneumonia

G. Pappas Clinical Microbiology and Infection

Metagenomics and probiotics

Effect of antioxidants on the immune response of Helicobacter pylori

Use of molecular typing to investigate bacterial translocation from the intestinal tract in malnourished children with Gram-negative bacteremia Mohammad.

Laboratory diagnosis of Clostridium difficile disease

Antimicrobial susceptibility of non-Bacteroides fragilis group anaerobic Gram-negative bacilli in Europe Anna King, Julie Downes, Carl-Erik Nord, Ian.

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

The practice of travel medicine in Europe

Effect of step-down therapy of ceftriaxone plus loracarbef versus parenteral therapy of ceftriaxone on the intestinal microflora in patients with community-acquired.

Community-acquired pneumonia: epidemiologic and clinical consideration

Abstracts cont. Clinical Microbiology and Infection

Pandemic lineages of extraintestinal pathogenic Escherichia coli

A novel fluorescence in situ hybridization test for rapid pathogen identification in positive blood cultures A. Makristathis, S. Riss, A.M. Hirschl

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci H.L. DuPont, Z.-D. Jiang Clinical Microbiology.

C.E. Nord, D.A. Gajjar, D.M. Grasela

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Overview of cefixime use in community-acquired infections

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

Virology: a scientific discipline facing new challenges

Modelling during an emergency: the 2009 H1N1 influenza pandemic

New oral cephalosporins in pediatric community-acquired infections

O. Megged, A.M. Yinnon, D. Raveh, B. Rudensky, Y. Schlesinger

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

Comparative study of pediculicidal effect of medical plants

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Oral supplementation with lactic acid-producing bacteria during intake of clindamycin Carl Erik Nord, Ann Lidbeck, Kerstin Orrhage, Svante Sjöstedt Clinical Microbiology and Infection Volume 3, Issue 1, Pages 124-132 (February 1997) DOI: 10.1111/j.1469-0691.1997.tb00262.x Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Effect of clindamycin and supplements containing lactic acid bacteria (LAB) or placebo on the (a) total intestinal microflora, (b) aerobic intestinal microflora, and (c) anaerobic intestinal microflora of 11 and 12 subjects, respectively. Mean values and standard errors (SE) are shown. Significant differences between the two groups. p = 0.02, *p < 0.05. Clinical Microbiology and Infection 1997 3, 124-132DOI: (10.1111/j.1469-0691.1997.tb00262.x) Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 2 Effect of clindamycin and supplements containing lactic acid bacteria or placebo on groups of the aerobic intestinal microflora in 11 and 12 subjects, respectively. The line represents interpolated geometric mean values. Note: ‘Enterobacteria’ comprise Gram-negative enterobacteria other than E. coli. Clinical Microbiology and Infection 1997 3, 124-132DOI: (10.1111/j.1469-0691.1997.tb00262.x) Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 3 Effect of clindamycin and supplements containing lactic acid bacteria or placebo on groups of the anaerobic intestinal microflora in 11 and 12 subjects, respectively. The line represents interpolated geometric mean values. Clinical Microbiology and Infection 1997 3, 124-132DOI: (10.1111/j.1469-0691.1997.tb00262.x) Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 4 Fecal mean pH of the two groups given clindamycin and lactic acid bacteria (LAB) or placebo. Clinical Microbiology and Infection 1997 3, 124-132DOI: (10.1111/j.1469-0691.1997.tb00262.x) Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions